Resmetirom, the long-awaited first treatment for metabolic dysfunction-associated steatohepatitis and liver fibrosis?

Abstract

The most important factor associated with liver-related mortality in NAFLD is liver fibrosis. There is no approved treatment for metabolic dysfunction-associated steatohepatitis (MASH) or liver fibrosis. In the MAESTRO-NASH trial, Harrison etal.1 demonstrated the efficacy of resmetirom, a selective THR-β agonist, for the treatment of MASH and liver fibrosis at 52weeks.